OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 01:05 UTC. Every row links to its source record.

SOCS1 suppressor of cytokine signaling 1

ENSG00000185338 · protein coding · Open Targets profile

Essential negative regulator of type I and type II interferon (IFN) signaling, as well as that of other cytokines, including IL2, IL4, IL6 and leukemia inhibitory factor (LIF) (PubMed:32499645, PubMed:33087723). Down-regulates cytokine signaling by inhibiting the JAK/STAT signaling pathway. Acts by binding to JAK proteins and to IFNGR1 and inhibiting their kinase activity. In vitro, suppresses Tec protein-tyrosine activity (PubMed:9341160). Regulates IFN-gamma (IFNG)- mediated sensory neuron survival (By similarity). Probable substrate recognition component of an ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:11278610, PubMed:11313480). {ECO:0000250|UniProtKB:O35716, ECO:0000269|PubMed:11278610, ECO:0000269|PubMed:11313480, ECO:0000269|PubMed:32499645, ECO:0000269|PubMed:33087723, ECO:0000269|PubMed:9341160}.

In 15 of 15 cancers, the evidence for SOCS1 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751diffuse large B-cell lymphomadiffuse large B-cell lymphomadiffuse large B-cell lymphoma: somatic 0.63lymphomalymphomalymphoma: somatic 0.61Hodgkins lymphomaHodgkins lymphomaHodgkins lymphoma: somatic 0.61lymphoid neoplasmlymphoid neoplasmlymphoid neoplasm: somatic 0.61non-functioning pituitary adenomanon-functioning pituitary adenomanon-functioning pituitary adenoma: somatic 0.61neoplasm of mature B-cellsneoplasm of mature B-cellsneoplasm of mature B-cells: somatic 0.61non-Hodgkin lymphomanon-Hodgkin lymphomanon-Hodgkin lymphoma: somatic 0.55hepatocellular carcinomahepatocellular carcinomahepatocellular carcinoma: somatic 0.46melanomamelanomamelanoma: somatic 0.46osteosarcomaosteosarcomaosteosarcoma: somatic 0.46head and neck squamous cell carcinomahead and neck squamous cell carcinomahead and neck squamous cell carcinoma: somatic 0.46lung carcinomalung carcinomalung carcinoma: somatic 0.46pancreatic ductal adenocarcinomapancreatic ductal adenocarcinomapancreatic ductal adenocarcinoma: somatic 0.46lung adenocarcinomalung adenocarcinomalung adenocarcinoma: somatic 0.46skin basal cell carcinomaskin basal cell carcinomaskin basal cell carcinoma: somatic 0.46

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

No positive tractability buckets.

gnomAD loss of function constraint: o/e 0.3094399869441986 (upper bound 0.799780011177063). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of SOCS1's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of SOCS1's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.